1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65911CAEB8BC4DACE8525796600554C6A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-science-liaison-internal-activities-and-oversight?opendocument
18
19opendocument
203.91.79.74
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Science Liaison

Medical Science Liaison Services Excellence: Managing Internal Activities and Providing Oversight

ID: 5177


Features:

11 Info Graphics

23 Data Graphics

160+ Metrics

6 Narratives


Pages/Slides: 41


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from " Medical Science Liaison Services Excellence: Managing Internal Activities and Providing Oversight"


STUDY OVERVIEW
Medical Science Liaisons are the bridge between a company's science and critical stakeholders in the marketplace. Recently, the responsibilities and services of MSLs have drawn more attention from executives due to the changing pharmaceutical environment. This study offers powerful insights that Medical Affairs leaders can use in the organization and deployment of MSLs. Additionally, this research provides information on how MSLs are targeting different customer bases and the oversight different companies provide to monitor their activities.

Specifically, Best Practices, LLC conducted this study to identify valuable insights into the organizational structure of MSLs and the level to which these MSLs provide services to different customer groups. The research explores FTE levels and span of control for MSLs as well as how they must adapt to regional idiosyncrasies. Biopharmaceutical and medical device executives can use this study to identify areas of internal weakness, as they try to globally standardized their organization of MSLs.

KEY TOPICS

  • MSLs Serving Different Customer Bases (e.g., Clinical Development Groups)
  • Future High Value Activities for MSLs
  • MSL Organization and Structure
  • Obstacles and Idiosyncrasies surrounding regional standardization

SAMPLE KEY METRICS
  • Ranking of most valuable MSL services when serving Medical Affairs, Clinical Development, Health Outcomes and Brand Team customers
  • Number of groups with functional responsibility for MSL and KOL management
  • Geographic span of responsibility for Medical Affairs
  • Number of MSL FTEs within your organization
  • Who has oversight responsibility for the MSL Function
  • How do you organize and provide KOL services through MSLs
  • Structures that work best to provide MSL services to Clinical Research Associates
  • Approach to developing global standards for MSLs across different regions

SAMPLE KEY FINDING
  • Medical Affairs POV -- KOLs Should Be Focus of MSLs: Medical Affairs wants MSLs to find and work with KOLs, as well as respond to unsolicited product information requests. Other highly rated activities are delivering presentations and speeches and gathering competitive intelligence
  • Span-of-Control of 9.5-to-1 for MSLs to Managers; Of the companies that had at least 6 FTEs for any of the following groups, respondents stated that they had on average 9.5 MSL FTEs for each MSL Manager and 11 for each MSL Director.
METHODOLOGY
Thirty-five research Pharmaceutical and Medical Device executives from 30 companies participated in this project. The benchmark class, of global pharmaceutical and medical device companies, has been segmented into two classes based on geographic coverage (Total Benchmark and U.S. focus).

Industries Profiled:
Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Advanced Biohealing; Allergan; Amylin; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Scientific; Cephalon; EndoPharma; Eisai; Gambro; G.E. Healthcare; Genetech; GlaxoSmithKline; Ironwood Pharma; Kadmon Pharma; Laboratorios Esteve; Lantheus Medical Imaging; Metronic; Merck Sharp and Dohme; Novartis; Novo Nordisk; Onyx Pharma; Pfizer; QLT; Quidel; Shire; Takeda; Theravance; UCB


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.